Women in Lymphoma: A 4-year journey in promoting gender equity

Judith Trotman; Ann LaCasce; Wendy Osborne; Anna Steiner; Eliza Hawkes; Carla Casulo; on behalf of the international Women in Lymphoma Steering Committee

doi:10.1002/hon.3183

Women in Lymphoma: A 4-year journey in promoting gender equity

Judith Trotman, Ann LaCasce, Wendy Osborne, Anna Steiner, Eliza Hawkes, Carla Casulo, on behalf of the international Women in Lymphoma Steering Committee

Research output: Contribution to journal › Comment / Debate › Other › peer-review

2 Citations (Scopus)

Original language	English
Article number	e3183
Number of pages	5
Journal	Hematological Oncology
Volume	42
Issue number	6
DOIs	https://doi.org/10.1002/hon.3183
Publication status	Published - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

gender equity
lymphoma
women

Access to Document

10.1002/hon.3183Licence: CC BY

Cite this

@article{5a8130667d3a46bcabf5c6d6dba10520,

title = "Women in Lymphoma: A 4-year journey in promoting gender equity",

keywords = "gender equity, lymphoma, women",

author = "Judith Trotman and Ann LaCasce and Wendy Osborne and Anna Steiner and Eliza Hawkes and Carla Casulo and \{on behalf of the international Women in Lymphoma Steering Committee\}",

note = "Funding Information: WiL has received funding support from the following pharmaceutical companies in unrestricted educational grants for the WiLing Wednesdays webinars: AstraZeneca, Beigene, BMS‐Celgene, Janssen, MSD, Mundipharma, Roche and SeaGen. ",

year = "2024",

month = nov,

doi = "10.1002/hon.3183",

language = "English",

volume = "42",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Women in Lymphoma

T2 - A 4-year journey in promoting gender equity

AU - Trotman, Judith

AU - LaCasce, Ann

AU - Osborne, Wendy

AU - Steiner, Anna

AU - Hawkes, Eliza

AU - Casulo, Carla

AU - on behalf of the international Women in Lymphoma Steering Committee

N1 - Funding Information: WiL has received funding support from the following pharmaceutical companies in unrestricted educational grants for the WiLing Wednesdays webinars: AstraZeneca, Beigene, BMS‐Celgene, Janssen, MSD, Mundipharma, Roche and SeaGen.

PY - 2024/11

Y1 - 2024/11

KW - gender equity

KW - lymphoma

KW - women

UR - https://www.scopus.com/pages/publications/85160613670

U2 - 10.1002/hon.3183

DO - 10.1002/hon.3183

M3 - Comment / Debate

C2 - 37231947

AN - SCOPUS:85160613670

SN - 0278-0232

VL - 42

JO - Hematological Oncology

JF - Hematological Oncology

IS - 6

M1 - e3183

ER -

Women in Lymphoma: A 4-year journey in promoting gender equity

UN SDGs

Keywords

Access to Document

Other files and links

Cite this